A1M Pharma has announced that the company has appointed Tobias Larsson Agervald as its new Chief Medical Officer (CMO).
Tobias Larsson Agervald is an associated professor and specialist in internal medicine and nephrology with extensive experience in global research and development of pharmaceuticals in both early and later clinical stages. He will assume the position 1 December, 2018.
As CMO, Tobias Larsson Agervald will be responsible for the overall medical strategy as well as designing, implementing and conducting A1M Pharma’s clinical development programme.
"We are pleased to welcome Tobias Larsson Agervald to our team. As a specialist in nephrology with experience in managing early and later stages of global clinical development, he will add a lot of value as we are now focusing on starting up and conducting our clinical program for ROSgard. Tobias is a global Key Opinion Leader in nephrology, and his broad international contacts will become very valuable as we prepare to launch upcoming clinical studies,” said Tomas Eriksson, A1M Pharma’s CEO.
“I am excited to start my assignment at A1M Pharma. The company has developed an interesting candidate drug with strong potential based on solid preclinical research. My experience tells me that there is an extensive medical need in kidney protection – the area that the company is now focusing on,” said Tobias Larsson Agervald.
